Meningococcal B vaccine development and evaluation of efficacy

被引：16

作者：

van Alphen, Loek ^{[1
]}

van den Dobbelsteen, Germie ^{[1
]}

机构：

[1] Netherlands Vaccine Inst, NL-3720 AL Bilthoven, Netherlands

来源：

HUMAN VACCINES | 2008年 / 4卷 / 02期

关键词：

meningococcal B; vaccine development; correlates of protection; serum bactericidal activity; clinical trials;

D O I：

10.4161/hv.4.2.4871

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In this commentary we stress that serum bactericidal activity is now internationally accepted as correlate of protection for evaluating new vaccines for epidemic and endemic meningococcal B control, and that the standardization of the assay and the choice of representative strains for each of the vaccine candidates are critical.

引用

页码：158 / 161

页数：4

共 30 条

[1] Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy [J].

Ameratunga, S ;

Macmillan, A ;

Stewart, J ;

Scott, D ;

Mulholland, K ;

Crengle, S .

VACCINE, 2005, 23 (17-18) :2231-2234

[2]

[Anonymous], NIPH ANN

[3]

BALMER P, 2003, EXPERT REV VACCINES, V3, P89

[4] Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine [J].

Beernink, Peter T. ;

Welsch, Jo Anne ;

Harrison, Lee H. ;

Leipus, Arunas ;

Kaplan, Sheldon L. ;

Granoff, Dan M. .

JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (10) :1472-1479

[5] EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY [J].

BJUNE, G ;

HOIBY, EA ;

GRONNESBY, JK ;

ARNESEN, O ;

HOLSTFREDRIKSEN, J ;

HALSTENSEN, A ;

HOLTEN, E ;

LINDBAK, AK ;

NOKLEBY, H ;

ROSENQVIST, E ;

SOLBERG, LK ;

CLOSS, O ;

ENG, J ;

FROHOLM, LO ;

LYSTAD, A ;

BAKKETEIG, LS ;

HAREIDE, B .

LANCET, 1991, 338 (8775) :1093-1096

[6] Neisseria meningitidis group B correlates of protection and assay standardization -: International meeting report Emory University, Atlanta, Georgia, United States, 16-17 march 2005 [J].

Borrow, R. ;

Carlone, G. M. ;

Rosenstein, N. ;

Plikaytis, B. ;

Blake, M. ;

Feavers, I. ;

Martin, D. ;

Zollinger, W. ;

Robbins, J. ;

Aaberge, I. ;

Granoff, D. M. ;

Miller, E. ;

van Alphen, L. ;

Poolman, J. ;

Rappuoli, R. ;

Danzig, L. ;

Hackell, J. ;

Danve, B. ;

Caulfield, M. ;

Lambert, S. ;

Stephens, D. .

VACCINE, 2006, 24 (24) :5093-5107

[7] Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection [J].

Borrow, R ;

Andrews, N ;

Goldblatt, D ;

Miller, E .

INFECTION AND IMMUNITY, 2001, 69 (03) :1568-1573

[8] Combination vaccine against invasive meningococcal B and pneumococcal infections -: Potential epidemiological and economic impact in The Netherlands [J].

Bos, JM ;

Rümke, HC ;

Welte, R ;

Spanjaard, L ;

van Alphen, L ;

Postma, MJ .

PHARMACOECONOMICS, 2006, 24 (02) :141-153

[9] EFFICACY, SAFETY, AND IMMUNOGENICITY OF A MENINGOCOCCAL GROUP-B (15-P1.3) OUTER-MEMBRANE PROTEIN VACCINE IN IQUIQUE, CHILE [J].

BOSLEGO, J ;

GARCIA, J ;

CRUZ, C ;

ZOLLINGER, W ;

BRANDT, B ;

RUIZ, S ;

MARTINEZ, M ;

ARTHUR, J ;

UNDERWOOD, P ;

SILVA, W ;

MORAN, E ;

HANKINS, W ;

GILLY, J ;

MAYS, J .

VACCINE, 1995, 13 (09) :821-829

[10] Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents [J].

Boutriau, Dominique ;

Poolman, Jan ;

Borrow, Ray ;

Findlow, Jamie ;

Diez Domingo, Javier ;

Puig-Barbera, Joan ;

Baldo, Jose Maria ;

Planelles, Victoria ;

Jubert, Angels ;

Colomer, Julia ;

Gil, Angel ;

Levie, Karin ;

Kervyn, Anne-Diane ;

Weynants, Vincent ;

Dominguez, Francisco ;

Barbera, Ramon ;

Sotolongo, Franklin .

CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (01) :65-73

← 1 2 3 →